Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom

Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Using a 1+1 Schedule in a National Immunization Schedule Having a Meningococcal Group B Vaccine as Standard of Care

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03632720

Enrollment

788

Registered

2018-08-15

Start date

2018-10-10

Completion date

2022-12-05

Last updated

2023-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteers (Meningococcal Infection)

Brief summary

The primary objective of the study was to demonstrate the non-inferiority of the antibody responses to meningococcal serogroups A, C, W, and Y (MenACYW) in terms of serum bactericidal assay using human complement (hSBA) vaccine seroprotection (antibody titer greater than or equal to \[\>=\] 1:8) when MenACYW Conjugate vaccine was administered concomitantly with Bexsero® in the second year of life compared to when MenACYW Conjugate vaccine was given alone. The secondary objectives were to compare the hSBA antibody response in terms of geometric mean titers (GMTs) against meningococcal serogroups A, C, W, and Y when MenACYW Conjugate vaccine was administered concomitantly with Bexsero® or when MenACYW Conjugate vaccine was given alone in the second year of life; to describe the hSBA and serum bactericidal assay using baby rabbit complement (rSBA) antibody responses against meningococcal serogroups A, C, W, and Y before and after the 1st dose of MenACYW Conjugate vaccine administered at 3 months of age, before and after the 2nd dose of MenACYW Conjugate vaccine administered at 12 to 13 months of age for Group 1 and Group 2; to describe the hSBA and rSBA antibody persistence against meningococcal serogroups A, C, W, and Y after the 1st dose of MenACYW Conjugate vaccine administered at 3 months of age for Group 1 and Group 2.

Detailed description

Study duration per participant was approximately 11 to 12 months.

Interventions

BIOLOGICALMeningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine

Pharmaceutical form: solution for injection; route of administration: intramuscular, 0.5 mL

BIOLOGICALMeningococcal group B vaccine

Pharmaceutical form: suspension for injection; route of administration: deep intramuscular, 0.5 mL

BIOLOGICALDiphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine

Pharmaceutical form: powder and suspension for suspension injection; route of administration: deep intramuscular, 0.5 mL

BIOLOGICALHuman rotavirus RIX4414 strain vaccine

Pharmaceutical form: oral suspension; route of administration: oral, 1.5 mL

BIOLOGICALPneumococcal 13-valent polysaccharide conjugate vaccine

Pharmaceutical form: suspension for injection; route of administration: intramuscular, 0.5 mL

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

56 Days to 89 Days

Healthy volunteers

Yes

Inclusion criteria

* Aged \>= 56 to less than or equal to (\<=) 89 days on the day of the first study visit. * Born at full term of pregnancy (\>= 37 weeks) and with a birth weight \>= 2.5 kilogram (kg) (or 5 lb and 8 oz). * Informed consent form had been signed and dated by the parent(s) or other legally acceptable representative (and by an independent witness if required by local regulations). * Participant and parent/legally acceptable representative were able to attend all scheduled visits and to comply with all trial procedures.

Exclusion criteria

\-- Participation at the time of study enrollment (or in the 4 weeks preceding the first trial vaccination) or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure. * Receipt of any vaccine in the 4 weeks preceding the first trial vaccination (at Visit 1) or planned receipt of any vaccine in the 4 weeks before and/or following any trial vaccination except for influenza vaccination, which may be received at a gap of at least 2 weeks before or 2 weeks after any study vaccines. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines. * Previous vaccination against meningococcal disease with either the trial vaccine or another vaccine (i.e., mono- or polyvalent, polysaccharide, or conjugate meningococcal vaccine containing serogroups A, C, W, or Y; or meningococcal B serogroup-containing vaccine). * Previous vaccination (before Visit 1) with any pneumococcal, diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b (Hib), poliovirus, and/or rotavirus vaccines. Receipt of BCG vaccine at birth was acceptable. * Receipt of immune globulins, blood or blood-derived since birth. * Known or suspected congenital or acquired immunodeficiency, including Severe Combined Immunodeficiency disorder (SCID); or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks) since birth. * History of any neurologic disorders, including any seizures and progressive neurologic disorders or encephalopathy. * History of Neisseria meningitidis infection, confirmed either clinically, serologically, or microbiologically. * History of diphtheria, tetanus, pertussis, poliomyelitis, Hib, hepatitis B, Streptococcus pneumoniae, and/or rotavirus infection or disease. * At high risk for meningococcal infection during the trial (specifically, but not limited to, participants with persistent complement deficiency, with anatomic or functional asplenia, or participants travelling to countries with high endemic or epidemic disease). * History of Guillain-Barré syndrome. * Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances including neomycin, kanamycin, polymyxin, formaldehyde, and latex. * Hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency. * History of intussusception or uncorrected congenital malformation of the gastrointestinal tract that would predispose to intussusception. * Verbal report of thrombocytopenia, contraindicating intramuscular vaccination in the investigator's opinion. * Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination. * Chronic illness that, in the opinion of the investigator, was at a stage where it might interfere with trial conduct or completion. * Any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives, including planning to leave the area of the study site before the end of the study. * Moderate or severe acute illness/infection (according to investigator judgment), or febrile illness (temperature \>= 38.0°C), or diarrhea or vomiting on the day of vaccination. A prospective participant should not be included in the study until the condition had resolved or the febrile event has subsided. * Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study.

Design outcomes

Primary

Measure	Time frame	Description
Percentage of Participants With Antibody Titers Greater Than or Equal to (>=) 1:8 Against Meningococcal Serogroups A, C, Y, and W Measured by hSBA After Vaccination: Groups 1 and 2 - PPAS3	30 days post-vaccination at the age of 12 to 13 months (i.e., at the age of 13 to 14 months)	Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by serum bactericidal assay using human complement (hSBA) assay. Percentage of participants with antibody titers \>=1:8 for meningococcal serogroups A, C, Y, and W were reported in this outcome measure. Data for this outcome measure was not planned to be collected and analyzed for Group 3.

Secondary

Measure	Time frame	Description
Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Before vaccination at the age of 3 months	GMTs of antibody against meningococcal serogroups A, C, Y, and W were measured by hSBA. Infancy was defined as up to 4 months of age. Titers were expressed in terms of 1/dilution. Data for this outcome measure was not planned to be collected and analyzed for Group 3.
Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	30 days post-vaccination at the age of 3 months (i.e., at the age of 4 months)	GMTs of antibody against meningococcal serogroups A, C, Y, and W were measured by hSBA. Infancy was defined as up to 4 months of age. Titers were expressed in terms of 1/dilution. Data for this outcome measure was not planned to be collected and analyzed for Group 3.
Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Before vaccination at the age of 12 to 13 months	GMTs of antibodies against meningococcal serogroups A, C, Y, and W were measured by hSBA. Infancy was defined as up to 4 months of age. Titers were expressed in terms of 1/dilution.
Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	30 days post-vaccination at the age of 12 to 13 months (i.e., at the age of 13 to 14 months)	GMTs of antibodies against meningococcal serogroups A, C, Y, and W were measured by hSBA. Titers were expressed in terms of 1/dilution.
Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Before vaccination at the age of 3 months	GMTs of antibodies against meningococcal serogroups A, C, Y, and W were measured by serum bactericidal assay using baby rabbit complement (rSBA). Infancy was defined as up to 4 months of age. Titers were expressed in terms of 1/dilution.
Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	30 days post-vaccination at the age of 3 months (i.e., at the age of 4 months)	GMTs of antibodies against meningococcal serogroups A, C, Y, and W were measured by rSBA. Infancy was defined as up to 4 months of age. Titers were expressed in terms of 1/dilution.
Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Before vaccination at the age of 12 to 13 months	GMTs of antibody against meningococcal serogroups A, C, Y, and W were measured by rSBA. Titers were expressed in terms of 1/dilution.
Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	30 days post-vaccination at the age of 12 to 13 months (i.e., at the age of 13 to 14 months)	GMTs of antibody against meningococcal serogroups A, C, Y, and W were measured by rSBA. Titers were expressed in terms of 1/dilution.
Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Before vaccination at the age of 3 months	Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Infancy was defined as up to 4 months of age. Percentage of participants with antibody titers \>=1.4 and \>=1:8 for meningococcal serogroups A, C, Y, and W were reported in this outcome measure.
Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	30 days post-vaccination at the age of 3 months (i.e., at the age of 4 months)	Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Infancy was defined as up to 4 months of age. Percentage of participants with antibody titers \>=1.4 and \>=1:8 for meningococcal serogroups A, C, Y, and W were reported in this outcome measure.
Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Before vaccination at the age of 12 to 13 months	Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Infancy was defined as up to 4 months of age. Percentage of participants with antibody titers \>=1.4 and \>=1:8 for meningococcal serogroups A, C, Y, and W were reported in this outcome measure.
Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	30 days post-vaccination at the age of 12 to 13 months (i.e., at the age of 13 to 14 months)	Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Percentage of participants with antibody titers \>=1.4 and \>=1:8 for meningococcal serogroups A, C, Y, and W were reported in this outcome measure.
Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Before vaccination at the age of 3 months	Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by rSBA assay. Infancy was defined as up to 4 months of age. Percentage of participants with antibody titers \>=1.8 and \>=1:128 for meningococcal serogroups A, C, Y, and W were reported in this outcome measure.
Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	30 days post-vaccination at the age of 3 months (i.e., at the age of 4 months)	Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by rSBA assay. Infancy was defined as up to 4 months of age. Percentage of participants with antibody titers \>=1.8 and \>=1:128 for meningococcal serogroups A, C, Y, and W were reported in this outcome measure.
Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Before vaccination at the age of 12 to 13 months	Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by rSBA assay. Infancy was defined as up to 4 months of age. Percentage of participants with antibody titers \>=1.8 and \>=1:128 for meningococcal serogroups A, C, Y, and W were reported in this outcome measure.
Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	30 days post-vaccination at the age of 12 to 13 months (i.e., at the age of 13 to 14 months)	Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by rSBA assay. Percentage of participants with antibody titers \>=1.8 and \>=1:128 for meningococcal serogroups A, C, Y, and W were reported in this outcome measure.
Percentage of Participants With >= 4-Fold Rise in hSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Before vaccination at the age of 3 months, 30 days post-vaccination at the age of 3 months (i.e., at the age of 4 months)	Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Fold-rise was calculated as ratio of post-vaccination titer (i.e., 30 days post-vaccination at the age of 3 months) to pre-dose titer at the age of 3 months. Infancy was defined as up to 4 months of age.
Percentage of Participants With >= 4-Fold Rise in hSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Before vaccination at the age of 3 months, 30 days post-vaccination at the age of 12 to 13 months (i.e., at the age of 13 to 14 months)	Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Fold-rise was calculated as ratio of post-vaccination titer (i.e., 30 days post-vaccination at the age of 12 to 13 months) to pre-dose titer before vaccination at the age of 3 months.
Percentage of Participants With >= 4-Fold Rise in rSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Before vaccination at the age of 3 months, 30 days post-vaccination at the age of 3 months (i.e., at the age of 4 months)	Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by rSBA assay. Fold-rise was calculated as ratio of post-vaccination titer (i.e., 30 days post-vaccination at the age of 3 months) to pre-dose titer at the age of 3 months. Infancy was defined as up to 4 months of age.
Geometric Mean Titers (GMTs) of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	30 days post-vaccination at the age of 12 to 13 months (i.e., at the age of 13 to 14 months)	GMTs of antibody against meningococcal serogroups A, C, Y, and W were measured by hSBA. Titers were expressed in terms of 1/dilution.
Percentage of Participants With Vaccine Seroresponse Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Before vaccination at the age of 3 months up to 30 days post-vaccination at the age of 3 months (i.e., at the age of 4 months)	The hSBA vaccine seroresponse against serogroups A, C, Y, and W was defined as post-vaccination hSBA titer \>=1:16 for participants with pre-vaccination hSBA titer \<1:8 or at least a 4-fold increase in hSBA titers from pre to post-vaccination for participants with pre-vaccination hSBA titers \>=1:8. Infancy was defined as up to 4 months of age.
Percentage of Participants With Vaccine Seroresponse Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Before vaccination at the age of 3 months up to 30 days post-vaccination at the age of 12 to 13 months (i.e., at the age of 13 to 14 months)	The hSBA vaccine seroresponse against serogroups A, C, Y, and W was defined as post-vaccination hSBA titer \>=1:16 for participants with pre-vaccination hSBA titer \<1:8 or at least a 4-fold increase in hSBA titers from pre to post-vaccination for participants with pre-vaccination hSBA titers \>=1:8.
Percentage of Participants With Vaccine Seroresponse Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Before vaccination at the age of 3 months up to 30 days post-vaccination at the age of 3 months (i.e., at the age of 4 months)	The rSBA vaccine seroresponse against serogroups A, C, Y, and W was defined as post-vaccination rSBA titer \>=1:32 for participants with pre-vaccination rSBA titer \<1:8 or at least a 4-fold increase in hSBA titers from pre to post-vaccination for participants with pre-vaccination hSBA titers \>=1:8. Infancy was defined as up to 4 months of age.
Percentage of Participants With Vaccine Seroresponse Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Before vaccination at the age of 3 months up to 30 days post-vaccination at the age of 12 to 13 months (i.e., at the age of 13 to 14 months)	The rSBA vaccine seroresponse against serogroups A, C, Y, and W was defined as post-vaccination rSBA titer \>=1:32 for participants with pre-vaccination rSBA titer \<1:8 or at least a 4-fold increase in hSBA titers from pre to post-vaccination for participants with pre-vaccination hSBA titers \>=1:8.
Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Before vaccination at the age of 3 months	Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Percentage of participants with hSBA antibody titers distribution \<1:4, \>=1:4, \>=1:8, \>=1:16; \>=1:32; \>=1:64, \>=1:128, \>=1:256; \>=1:512; \>=1:1024 for meningococcal serogroups A, C, Y, and W were reported in this outcome measure.
Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	30 days post-vaccination at the age of 3 months (i.e., at the age of 4 months)	Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Infancy was defined as up to 4 months of age. Percentage of participants with hSBA antibody titers distribution \<1:4, \>=1:4, \>=1:8, \>=1:16; \>=1:32; \>=1:64, \>=1:128, \>=1:256; \>=1:512; \>=1:1024 for meningococcal serogroups A, C, Y, and W were reported in this outcome measure.
Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Before vaccination at the age of 12 to 13 months	Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Infancy was defined as up to 4 months of age. Percentage of participants with hSBA antibody titers distribution \<1:4, \>=1:4, \>=1:8, \>=1:16; \>=1:32; \>=1:64, \>=1:128, \>=1:256; \>=1:512; \>=1:1024; \>=1:2048; \>=1:4096; \>=1:8192; \>=1:16384; \>=1:32768; \>=1:65536 for meningococcal serogroups A, C, Y, and W were reported in this outcome measure.
Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	30 days post-vaccination at the age of 3 months (i.e., at the age of 4 months) and before vaccination at the age of 12-13 months	Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Percentage of participants with hSBA antibody titers \>=1.4 and \>=1:8 for meningococcal serogroups A, C, Y, and W were reported in this outcome measure.
Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	30 days post-vaccination at the age of 12 to 13 months (i.e., at the age of 13 to 14 months)	Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Percentage of participants with hSBA antibody titers distribution \<1:4, \>=1:4, \>=1:8, \>=1:16; \>=1:32; \>=1:64, \>=1:128, \>=1:256; \>=1:512; \>=1:1024; \>=1:2048; \>=1:4096; \>=1:8192; \>=1:16384; \>=1:32768; \>=1:65536 for meningococcal serogroups A, C, Y, and W were reported in this outcome measure.
Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Before vaccination at the age of 3 months	Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by rSBA assay. Infancy was defined as up to 4 months of age. Percentage of participants with rSBA antibody titers distribution \<1:4, \>=1:4, \>=1:8, \>=1:16; \>=1:32; \>=1:64, \>=1:128, \>=1:256; \>=1:512; \>=1:1024; \>=1:2048; \>=1:4096; \>=1:8192 for meningococcal serogroups A, C, Y, and W were reported in this outcome measure.
Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	30 days post-vaccination at the age of 3 months (i.e., at the age of 4 months)	Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by rSBA assay. Infancy was defined as up to 4 months of age. Percentage of participants with rSBA antibody titers distribution \<1:4, \>=1:4, \>=1:8, \>=1:16; \>=1:32; \>=1:64, \>=1:128, \>=1:256; \>=1:512; \>=1:1024; \>=1:2048; \>=1:4096; \>=1:8192 for meningococcal serogroups A, C, Y, and W were reported in this outcome measure.
Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Before vaccination at the age of 12 to 13 months	Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by rSBA assay. Infancy was defined as up to 4 months of age. Percentage of participants with rSBA antibody titers distribution \<1:4, \>=1:4, \>=1:8, \>=1:16; \>=1:32; \>=1:64, \>=1:128, \>=1:256; \>=1:512; \>=1:1024; \>=1:2048; \>=1:4096; \>=1:8192; \>=1:16384; \>=1:32768 for meningococcal serogroups A, C, Y, and W were reported in this outcome measure.
Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	30 days post-vaccination at the age of 12 to 13 months (i.e., at the age of 13 to 14 months)	Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by rSBA assay. Percentage of participants with rSBA antibody titers distribution \<1:4, \>=1:4, \>=1:8, \>=1:16; \>=1:32; \>=1:64, \>=1:128, \>=1:256; \>=1:512; \>=1:1024; \>=1:2048; \>=1:4096; \>=1:8192; \>=1:16384; \>=1:32768 for meningococcal serogroups A, C, Y, and W were reported in this outcome measure.
Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2	30 days post-vaccination at the age of 3 months (i.e., at the age of 4 months) and before vaccination at the age of 12-13 months	GMTs of antibody against meningococcal serogroups A, C, Y, and W were measured by hSBA. Titers were expressed in terms of 1/dilution.
Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2	30 days post-vaccination at the age of 3 months (i.e., at the age of 4 months) and before vaccination at the age of 12-13 months	GMTs of antibody against meningococcal serogroups A, C, Y, and W were measured by rSBA. Titers were expressed in terms of 1/dilution.
Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	30 days post-vaccination at the age of 3 months (i.e., at the age of 4 months) and before vaccination at the age of 12-13 months	Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by rSBA assay. Percentage of participants with rSBA antibody titers \>=1:8 and \>=1:128 for meningococcal serogroups A, C, Y, and W were reported in this outcome measure.
Number of Participants With Solicited Injection Site Reactions After Any Vaccination	Within 7 days post any vaccination	A solicited reaction (SR) was defined as an expected adverse reaction (AR) (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed (i.e., solicited) in the protocol and case report form (CRF) and considered as related to vaccination. Solicited injection site reactions included injection site tenderness, injection site erythema, and injection site swelling and were planned to be collected and reported for each vaccine separately; and not planned to be collected for Rotavirus vaccine as the vaccine was administered orally, and no injection site reactions were expected to occur. Reported AEs for each arm were presented as pre-specified in the study protocol. Here, '0' in number analyzed field for MenACYW categories signifies that no participant was evaluable because in Group 3 MenACYW vaccine was not administered.
Number of Participants With Solicited Systemic Reactions After Any Vaccination	Within 7 days after any vaccination	A SR was an expected AR (sign or symptom) observed and reported under the conditions (nature and onset) prelisted (i.e., solicited) in the CRB and considered as related to the product administered. Solicited systemic reactions included fever, vomiting, crying abnormal, drowsiness, appetite lost, and irritability. Reported AEs for each arm were presented as pre-specified in the study protocol.
Percentage of Participants With >= 4-Fold Rise in rSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Before vaccination at the age of 3 months, 30 days post-vaccination at the age of 12 to 13 months (i.e., at the age of 13 to 14 months)	Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by rSBA assay. Fold-rise was calculated as ratio of post-vaccination titer (i.e., 30 days post-vaccination at the age of 12 to 13 months) to pre-dose titer before vaccination at the age of 3 months.

Countries

United Kingdom

Participant flow

Recruitment details

Study was conducted at 16 sites in United Kingdom from 10 October 2018 to 05 December 2022.

Pre-assignment details

A total of 788 participants were enrolled and randomized in the study.

Participants by arm

Arm	Count
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months) Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at 3 months and at 12 to 13 months of age, Bexsero® at 2, 4, and 12 to 13 months of age along with Infanrix hexa® vaccine at 2, 3, and 4 months of age; Rotarix® vaccine at 2 and 3 months of age; and Prevenar 13® vaccine at 2 and 4 months of age.	314
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months) Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at 3 months and at 12 to 13 months of age, Bexsero® at 2 and 4 months of age along with Infanrix hexa® vaccine at 2, 3, and 4 months of age; Rotarix® vaccine at 2 and 3 months of age; and Prevenar 13® vaccine at 2 and 4 months of age.	316
Group 3: Bexsero® (2, 4, and 12 to 13 Months) Participants aged 2 months (at the time of enrollment) received Bexsero® at 2, 4, and 12 to 13 months of age along with Infanrix hexa® vaccine at 2, 3, and 4 months of age; Rotarix® vaccine at 2 and 3 months of age; and Prevenar 13® vaccine at 2 and 4 months of age.	158
Total	788

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002
Overall Study	Adverse Event	2	0	0
Overall Study	Lost to Follow-up	0	1	0
Overall Study	Screen failure	0	1	0
Overall Study	Withdrawal by parent/legally acceptable representative	11	9	8

Baseline characteristics

Characteristic	Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Total	Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)
Age, Continuous	64.7 days STANDARD_DEVIATION 6.88	64.4 days STANDARD_DEVIATION 6.85	64.8 days STANDARD_DEVIATION 7.03	63.9 days STANDARD_DEVIATION 6.73
Race (NIH/OMB) American Indian or Alaska Native	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Asian	1 Participants	9 Participants	4 Participants	4 Participants
Race (NIH/OMB) Black or African American	0 Participants	2 Participants	0 Participants	2 Participants
Race (NIH/OMB) More than one race	4 Participants	18 Participants	4 Participants	10 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Unknown or Not Reported	9 Participants	15 Participants	2 Participants	4 Participants
Race (NIH/OMB) White	300 Participants	744 Participants	148 Participants	296 Participants
Sex/Gender, Customized Female	148 Participants	383 Participants	81 Participants	154 Participants
Sex/Gender, Customized Male	166 Participants	404 Participants	77 Participants	161 Participants
Sex/Gender, Customized Missing	0 Participants	1 Participants	0 Participants	1 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk
deaths Total, all-cause mortality	0 / 314	0 / 314	0 / 157
other Total, other adverse events	310 / 314	310 / 314	155 / 157
serious Total, serious adverse events	18 / 314	34 / 314	7 / 157

Outcome results

Primary

Percentage of Participants With Antibody Titers Greater Than or Equal to (>=) 1:8 Against Meningococcal Serogroups A, C, Y, and W Measured by hSBA After Vaccination: Groups 1 and 2 - PPAS3

Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by serum bactericidal assay using human complement (hSBA) assay. Percentage of participants with antibody titers \>=1:8 for meningococcal serogroups A, C, Y, and W were reported in this outcome measure. Data for this outcome measure was not planned to be collected and analyzed for Group 3.

Time frame: 30 days post-vaccination at the age of 12 to 13 months (i.e., at the age of 13 to 14 months)

Population: Analysis was performed on Per-Protocol Analysis Set 3 (PPAS3) defined for accessing ACYW immune response data for participants who received at least 1 dose of study vaccine and had valid post-vaccination serology results of 2nd year of life, with no relevant protocol deviation. Here, 'number analyzed' = participants with available data for each specified category.

Arm	Measure	Group	Value (NUMBER)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Antibody Titers Greater Than or Equal to (>=) 1:8 Against Meningococcal Serogroups A, C, Y, and W Measured by hSBA After Vaccination: Groups 1 and 2 - PPAS3	Serogroup A	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Antibody Titers Greater Than or Equal to (>=) 1:8 Against Meningococcal Serogroups A, C, Y, and W Measured by hSBA After Vaccination: Groups 1 and 2 - PPAS3	Serogroup Y	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Antibody Titers Greater Than or Equal to (>=) 1:8 Against Meningococcal Serogroups A, C, Y, and W Measured by hSBA After Vaccination: Groups 1 and 2 - PPAS3	Serogroup W	99.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Antibody Titers Greater Than or Equal to (>=) 1:8 Against Meningococcal Serogroups A, C, Y, and W Measured by hSBA After Vaccination: Groups 1 and 2 - PPAS3	Serogroup C	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Antibody Titers Greater Than or Equal to (>=) 1:8 Against Meningococcal Serogroups A, C, Y, and W Measured by hSBA After Vaccination: Groups 1 and 2 - PPAS3	Serogroup W	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Antibody Titers Greater Than or Equal to (>=) 1:8 Against Meningococcal Serogroups A, C, Y, and W Measured by hSBA After Vaccination: Groups 1 and 2 - PPAS3	Serogroup A	99.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Antibody Titers Greater Than or Equal to (>=) 1:8 Against Meningococcal Serogroups A, C, Y, and W Measured by hSBA After Vaccination: Groups 1 and 2 - PPAS3	Serogroup C	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Antibody Titers Greater Than or Equal to (>=) 1:8 Against Meningococcal Serogroups A, C, Y, and W Measured by hSBA After Vaccination: Groups 1 and 2 - PPAS3	Serogroup Y	100 percentage of participants

Comparison: Serogroup A95% CI: [-1.78, 3.54]

Comparison: Serogroup C95% CI: [-2.24, 2.28]

Comparison: Serogroup Y95% CI: [-2.33, 2.36]

Comparison: Serogroup W95% CI: [-3.22, 1.81]

Secondary

Geometric Mean Titers (GMTs) of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3

GMTs of antibody against meningococcal serogroups A, C, Y, and W were measured by hSBA. Titers were expressed in terms of 1/dilution.

Time frame: 30 days post-vaccination at the age of 12 to 13 months (i.e., at the age of 13 to 14 months)

Population: Analysis was performed on PPAS3. Here, 'number analyzed' = participants with available data for each specified category. Data for this outcome measure was not planned to be collected and analyzed for Group 3.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers (GMTs) of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup A	1214 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers (GMTs) of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup C	963 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers (GMTs) of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup Y	454 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers (GMTs) of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup W	578 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers (GMTs) of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup W	528 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers (GMTs) of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup A	205 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers (GMTs) of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup Y	434 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers (GMTs) of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup C	744 titers

Secondary

Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1

GMTs of antibody against meningococcal serogroups A, C, Y, and W were measured by hSBA. Infancy was defined as up to 4 months of age. Titers were expressed in terms of 1/dilution. Data for this outcome measure was not planned to be collected and analyzed for Group 3.

Time frame: 30 days post-vaccination at the age of 3 months (i.e., at the age of 4 months)

Population: Analysis was performed PPAS1. Here, 'number analyzed' = participants with available data for each specified category.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup A	10.8 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup C	78.0 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup Y	9.44 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup W	4.67 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup W	3.81 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup A	9.63 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup Y	6.33 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup C	61.2 titers

Secondary

Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3

GMTs of antibodies against meningococcal serogroups A, C, Y, and W were measured by hSBA. Titers were expressed in terms of 1/dilution.

Time frame: 30 days post-vaccination at the age of 12 to 13 months (i.e., at the age of 13 to 14 months)

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup A	1214 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup Y	454 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup C	963 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup W	578 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup C	744 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup A	205 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup W	528 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup Y	434 titers

Secondary

Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1

Time frame: Before vaccination at the age of 3 months

Population: Analysis was performed on per-protocol analysis set 1 (PPAS1) defined for accessing ACYW immune response data for participants who received at least 1 dose of study vaccine and had valid post-vaccination serology result of infancy (up to 4 months age) vaccination stage, with no relevant protocol deviations. Here, 'number analyzed' = participants with available data for each specified category.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup A	8.52 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup C	3.70 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup Y	3.26 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup W	2.52 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup W	2.15 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup A	7.22 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup Y	2.58 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup C	3.84 titers

Secondary

Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3

GMTs of antibodies against meningococcal serogroups A, C, Y, and W were measured by hSBA. Infancy was defined as up to 4 months of age. Titers were expressed in terms of 1/dilution.

Time frame: Before vaccination at the age of 12 to 13 months

Population: Analysis was performed on PPAS3. Here, 'overall number of participants analyzed' = participants with available data for this outcome measure and 'number analyzed' = participants with available data for each specified category. Data for this outcome measure was not planned to be collected and analyzed for Group 3.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup C	30.2 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup A	45.8 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup Y	25.2 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup W	34.6 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup W	10.4 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup Y	9.90 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup A	22.6 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup C	8.44 titers

Secondary

Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2

GMTs of antibody against meningococcal serogroups A, C, Y, and W were measured by hSBA. Titers were expressed in terms of 1/dilution.

Time frame: 30 days post-vaccination at the age of 3 months (i.e., at the age of 4 months) and before vaccination at the age of 12-13 months

Population: Analysis was performed on per-protocol analysis set 2 (PPAS2) defined for accessing ACYW immune response data for participants who received at least 1 dose of study vaccine in infancy and had valid post-vaccination serology results at 12 to13 months of age, with no relevant protocol violations. Here, 'number analyzed' = participants with available data for each specified category. Data for this outcome measure was not planned to be collected and analyzed for Group 3.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2	Serogroup A: Before 12-13 months vaccination	46.1 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2	Serogroup C: 30 days after 3-month vaccination	95.1 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2	Serogroup C: Before 12-13 months vaccination	24.4 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2	Serogroup Y: 30 days after 3-month vaccination	9.69 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2	Serogroup Y: Before 12-13 months vaccination	21.4 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2	Serogroup W: 30 days after 3-month vaccination	4.32 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2	Serogroup W: Before 12-13 months vaccination	29.4 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2	Serogroup A: 30 days after 3-month vaccination	12.7 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2	Serogroup A: 30 days after 3-month vaccination	9.28 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2	Serogroup A: Before 12-13 months vaccination	31.4 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2	Serogroup Y: Before 12-13 months vaccination	12.4 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2	Serogroup C: 30 days after 3-month vaccination	59.4 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2	Serogroup W: Before 12-13 months vaccination	11.2 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2	Serogroup C: Before 12-13 months vaccination	16.6 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2	Serogroup W: 30 days after 3-month vaccination	3.62 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2	Serogroup Y: 30 days after 3-month vaccination	4.95 titers

Secondary

Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1

GMTs of antibodies against meningococcal serogroups A, C, Y, and W were measured by rSBA. Infancy was defined as up to 4 months of age. Titers were expressed in terms of 1/dilution.

Time frame: 30 days post-vaccination at the age of 3 months (i.e., at the age of 4 months)

Population: Analysis was performed on PPAS1. Here, 'overall number of participants analyzed' = participants with available data for this outcome measure and 'number analyzed' = participants with available data for each specified category. Data for this outcome measure was not planned to be collected and analyzed for Group 3.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup A	13.7 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup C	251 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup Y	152 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup W	87.1 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup W	50.8 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup A	20.7 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup Y	124 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup C	347 titers

Secondary

Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3

GMTs of antibody against meningococcal serogroups A, C, Y, and W were measured by rSBA. Titers were expressed in terms of 1/dilution.

Time frame: 30 days post-vaccination at the age of 12 to 13 months (i.e., at the age of 13 to 14 months)

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup A	1741 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup Y	2620 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup C	1396 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup W	2491 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup C	1532 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup A	1508 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup W	2566 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup Y	1414 titers

Secondary

Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1

GMTs of antibodies against meningococcal serogroups A, C, Y, and W were measured by serum bactericidal assay using baby rabbit complement (rSBA). Infancy was defined as up to 4 months of age. Titers were expressed in terms of 1/dilution.

Time frame: Before vaccination at the age of 3 months

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup A	2.00 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup C	2.88 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup Y	2.68 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup W	2.89 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup W	2.00 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup A	2.00 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup Y	2.70 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup C	3.77 titers

Secondary

Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3

GMTs of antibody against meningococcal serogroups A, C, Y, and W were measured by rSBA. Titers were expressed in terms of 1/dilution.

Time frame: Before vaccination at the age of 12 to 13 months

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup A	32.0 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup C	58.0 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup Y	58.0 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup W	8.00 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup W	8.00 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup A	169 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup Y	6.96 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup C	3.48 titers

Secondary

Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2

GMTs of antibody against meningococcal serogroups A, C, Y, and W were measured by rSBA. Titers were expressed in terms of 1/dilution.

Time frame: 30 days post-vaccination at the age of 3 months (i.e., at the age of 4 months) and before vaccination at the age of 12-13 months

Population: Analysis was performed on PPAS2. Here, 'overall number of participants analyzed' = participants with available data for this outcome measure and 'number analyzed' = participants with available data for each specified category. Data for this outcome measure was not planned to be collected and analyzed for Group 3.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2	Serogroup A: 30 days after 3-month vaccination	80.6 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2	Serogroup A: Before 12-13 months vaccination	21.5 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2	Serogroup C: 30 days after 3-month vaccination	431 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2	Serogroup C: Before 12-13 months vaccination	38.1 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2	Serogroup Y: 30 days after 3-month vaccination	323 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2	Serogroup Y: Before 12-13 months vaccination	69.8 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2	Serogroup W: 30 days after 3-month vaccination	256 titers
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2	Serogroup W: Before 12-13 months vaccination	16.0 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2	Serogroup W: Before 12-13 months vaccination	4.67 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2	Serogroup A: 30 days after 3-month vaccination	18.0 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2	Serogroup Y: 30 days after 3-month vaccination	102 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2	Serogroup A: Before 12-13 months vaccination	27.4 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2	Serogroup W: 30 days after 3-month vaccination	90.5 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2	Serogroup C: 30 days after 3-month vaccination	144 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2	Serogroup Y: Before 12-13 months vaccination	20.7 titers
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2	Serogroup C: Before 12-13 months vaccination	11.8 titers

Secondary

Number of Participants With Solicited Injection Site Reactions After Any Vaccination

A solicited reaction (SR) was defined as an expected adverse reaction (AR) (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed (i.e., solicited) in the protocol and case report form (CRF) and considered as related to vaccination. Solicited injection site reactions included injection site tenderness, injection site erythema, and injection site swelling and were planned to be collected and reported for each vaccine separately; and not planned to be collected for Rotavirus vaccine as the vaccine was administered orally, and no injection site reactions were expected to occur. Reported AEs for each arm were presented as pre-specified in the study protocol. Here, '0' in number analyzed field for MenACYW categories signifies that no participant was evaluable because in Group 3 MenACYW vaccine was not administered.

Time frame: Within 7 days post any vaccination

Population: Analysis was performed on safety analysis set. Here, 'number analyzed' = participants with available data for each specified category.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Number of Participants With Solicited Injection Site Reactions After Any Vaccination	Prevnar 13: Tenderness	195 Participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Number of Participants With Solicited Injection Site Reactions After Any Vaccination	Prevnar 13: Erythema	214 Participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Number of Participants With Solicited Injection Site Reactions After Any Vaccination	Bexsero: Tenderness	266 Participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Number of Participants With Solicited Injection Site Reactions After Any Vaccination	Prevnar 13: Swelling	140 Participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Number of Participants With Solicited Injection Site Reactions After Any Vaccination	Bexsero: Erythema	271 Participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Number of Participants With Solicited Injection Site Reactions After Any Vaccination	MenACYW conjugate vaccine: Tenderness	198 Participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Number of Participants With Solicited Injection Site Reactions After Any Vaccination	Bexsero: Swelling	234 Participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Number of Participants With Solicited Injection Site Reactions After Any Vaccination	MenACYW conjugate vaccine: Erythema	220 Participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Number of Participants With Solicited Injection Site Reactions After Any Vaccination	Infanrix hexa: Tenderness	220 Participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Number of Participants With Solicited Injection Site Reactions After Any Vaccination	Infanrix hexa: Erythema	254 Participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Number of Participants With Solicited Injection Site Reactions After Any Vaccination	Infanrix hexa: Swelling	188 Participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Number of Participants With Solicited Injection Site Reactions After Any Vaccination	MenACYW conjugate vaccine: Swelling	139 Participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Number of Participants With Solicited Injection Site Reactions After Any Vaccination	MenACYW conjugate vaccine: Tenderness	161 Participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Number of Participants With Solicited Injection Site Reactions After Any Vaccination	Prevnar 13: Tenderness	196 Participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Number of Participants With Solicited Injection Site Reactions After Any Vaccination	MenACYW conjugate vaccine: Swelling	111 Participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Number of Participants With Solicited Injection Site Reactions After Any Vaccination	Infanrix hexa: Swelling	189 Participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Number of Participants With Solicited Injection Site Reactions After Any Vaccination	Prevnar 13: Erythema	202 Participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Number of Participants With Solicited Injection Site Reactions After Any Vaccination	Bexsero: Swelling	192 Participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Number of Participants With Solicited Injection Site Reactions After Any Vaccination	Infanrix hexa: Erythema	231 Participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Number of Participants With Solicited Injection Site Reactions After Any Vaccination	Prevnar 13: Swelling	137 Participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Number of Participants With Solicited Injection Site Reactions After Any Vaccination	Bexsero: Tenderness	230 Participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Number of Participants With Solicited Injection Site Reactions After Any Vaccination	MenACYW conjugate vaccine: Erythema	205 Participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Number of Participants With Solicited Injection Site Reactions After Any Vaccination	Infanrix hexa: Tenderness	216 Participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Number of Participants With Solicited Injection Site Reactions After Any Vaccination	Bexsero: Erythema	246 Participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Number of Participants With Solicited Injection Site Reactions After Any Vaccination	Prevnar 13: Swelling	69 Participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Number of Participants With Solicited Injection Site Reactions After Any Vaccination	Infanrix hexa: Tenderness	119 Participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Number of Participants With Solicited Injection Site Reactions After Any Vaccination	Bexsero: Erythema	136 Participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Number of Participants With Solicited Injection Site Reactions After Any Vaccination	Bexsero: Swelling	118 Participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Number of Participants With Solicited Injection Site Reactions After Any Vaccination	Infanrix hexa: Erythema	117 Participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Number of Participants With Solicited Injection Site Reactions After Any Vaccination	Infanrix hexa: Swelling	86 Participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Number of Participants With Solicited Injection Site Reactions After Any Vaccination	Prevnar 13: Tenderness	118 Participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Number of Participants With Solicited Injection Site Reactions After Any Vaccination	Prevnar 13: Erythema	104 Participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Number of Participants With Solicited Injection Site Reactions After Any Vaccination	Bexsero: Tenderness	138 Participants

Secondary

Number of Participants With Solicited Systemic Reactions After Any Vaccination

A SR was an expected AR (sign or symptom) observed and reported under the conditions (nature and onset) prelisted (i.e., solicited) in the CRB and considered as related to the product administered. Solicited systemic reactions included fever, vomiting, crying abnormal, drowsiness, appetite lost, and irritability. Reported AEs for each arm were presented as pre-specified in the study protocol.

Time frame: Within 7 days after any vaccination

Population: Analysis was performed on safety analysis set. Here, 'number analyzed' = participants with available data for each specified category.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Number of Participants With Solicited Systemic Reactions After Any Vaccination	Appetite lost	230 Participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Number of Participants With Solicited Systemic Reactions After Any Vaccination	Crying abnormal	293 Participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Number of Participants With Solicited Systemic Reactions After Any Vaccination	Irritability	306 Participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Number of Participants With Solicited Systemic Reactions After Any Vaccination	Fever	100 Participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Number of Participants With Solicited Systemic Reactions After Any Vaccination	Drowsiness	275 Participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Number of Participants With Solicited Systemic Reactions After Any Vaccination	Vomiting	173 Participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Number of Participants With Solicited Systemic Reactions After Any Vaccination	Drowsiness	275 Participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Number of Participants With Solicited Systemic Reactions After Any Vaccination	Appetite lost	230 Participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Number of Participants With Solicited Systemic Reactions After Any Vaccination	Vomiting	172 Participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Number of Participants With Solicited Systemic Reactions After Any Vaccination	Irritability	299 Participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Number of Participants With Solicited Systemic Reactions After Any Vaccination	Crying abnormal	273 Participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Number of Participants With Solicited Systemic Reactions After Any Vaccination	Fever	86 Participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Number of Participants With Solicited Systemic Reactions After Any Vaccination	Irritability	147 Participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Number of Participants With Solicited Systemic Reactions After Any Vaccination	Fever	50 Participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Number of Participants With Solicited Systemic Reactions After Any Vaccination	Vomiting	71 Participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Number of Participants With Solicited Systemic Reactions After Any Vaccination	Crying abnormal	141 Participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Number of Participants With Solicited Systemic Reactions After Any Vaccination	Drowsiness	137 Participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Number of Participants With Solicited Systemic Reactions After Any Vaccination	Appetite lost	121 Participants

Secondary

Percentage of Participants With >= 4-Fold Rise in hSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1

Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Fold-rise was calculated as ratio of post-vaccination titer (i.e., 30 days post-vaccination at the age of 3 months) to pre-dose titer at the age of 3 months. Infancy was defined as up to 4 months of age.

Time frame: Before vaccination at the age of 3 months, 30 days post-vaccination at the age of 3 months (i.e., at the age of 4 months)

Population: Analysis was performed on PPAS1. Here, 'number analyzed' = participants with available data for each specified category. Data for this outcome measure was not planned to be collected and analyzed for Group 3.

Arm	Measure	Group	Value (NUMBER)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With >= 4-Fold Rise in hSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup A	5.9 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With >= 4-Fold Rise in hSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup Y	45.8 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With >= 4-Fold Rise in hSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup C	70.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With >= 4-Fold Rise in hSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup W	29.2 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With >= 4-Fold Rise in hSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup C	82.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With >= 4-Fold Rise in hSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup A	25.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With >= 4-Fold Rise in hSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup W	18.5 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With >= 4-Fold Rise in hSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup Y	53.8 percentage of participants

Secondary

Percentage of Participants With >= 4-Fold Rise in hSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3

Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Fold-rise was calculated as ratio of post-vaccination titer (i.e., 30 days post-vaccination at the age of 12 to 13 months) to pre-dose titer before vaccination at the age of 12 to 13 months.

Time frame: Before vaccination at the age of 12 to 13 months, 30 days post-vaccination at the age of 12 to 13 months (i.e., at the age of 13 to 14 months)

Arm	Measure	Group	Value (NUMBER)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With >= 4-Fold Rise in hSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup A	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With >= 4-Fold Rise in hSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup C	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With >= 4-Fold Rise in hSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup Y	89.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With >= 4-Fold Rise in hSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup W	85.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With >= 4-Fold Rise in hSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup W	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With >= 4-Fold Rise in hSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup A	53.8 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With >= 4-Fold Rise in hSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup Y	96.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With >= 4-Fold Rise in hSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup C	100 percentage of participants

Secondary

Percentage of Participants With >= 4-Fold Rise in hSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3

Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Fold-rise was calculated as ratio of post-vaccination titer (i.e., 30 days post-vaccination at the age of 12 to 13 months) to pre-dose titer before vaccination at the age of 3 months.

Time frame: Before vaccination at the age of 3 months, 30 days post-vaccination at the age of 12 to 13 months (i.e., at the age of 13 to 14 months)

Arm	Measure	Group	Value (NUMBER)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With >= 4-Fold Rise in hSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup Y	96.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With >= 4-Fold Rise in hSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup A	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With >= 4-Fold Rise in hSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup W	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With >= 4-Fold Rise in hSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup C	92.9 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With >= 4-Fold Rise in hSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup W	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With >= 4-Fold Rise in hSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup A	91.7 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With >= 4-Fold Rise in hSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup Y	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With >= 4-Fold Rise in hSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup C	93.8 percentage of participants

Secondary

Percentage of Participants With >= 4-Fold Rise in rSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1

Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by rSBA assay. Fold-rise was calculated as ratio of post-vaccination titer (i.e., 30 days post-vaccination at the age of 3 months) to pre-dose titer at the age of 3 months. Infancy was defined as up to 4 months of age.

Time frame: Before vaccination at the age of 3 months, 30 days post-vaccination at the age of 3 months (i.e., at the age of 4 months)

Arm	Measure	Group	Value (NUMBER)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With >= 4-Fold Rise in rSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup A	46.2 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With >= 4-Fold Rise in rSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup C	86.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With >= 4-Fold Rise in rSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup Y	78.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With >= 4-Fold Rise in rSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup W	57.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With >= 4-Fold Rise in rSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup W	53.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With >= 4-Fold Rise in rSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup A	62.5 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With >= 4-Fold Rise in rSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup Y	90.9 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With >= 4-Fold Rise in rSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup C	87.5 percentage of participants

Secondary

Percentage of Participants With >= 4-Fold Rise in rSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3

Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by rSBA assay. Fold-rise was calculated as ratio of post-vaccination titer (i.e., 30 days post-vaccination at the age of 12 to 13 months) to pre-dose titer before vaccination at the age of 12 to 13 months.

Time frame: Before vaccination at the age of 12 to 13 months, 30 days post-vaccination at the age of 12 to 13 months (i.e., at the age of 13 to 14 months)

Arm	Measure	Group	Value (NUMBER)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With >= 4-Fold Rise in rSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup A	83.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With >= 4-Fold Rise in rSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup C	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With >= 4-Fold Rise in rSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup Y	71.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With >= 4-Fold Rise in rSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup W	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With >= 4-Fold Rise in rSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup W	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With >= 4-Fold Rise in rSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup A	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With >= 4-Fold Rise in rSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup Y	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With >= 4-Fold Rise in rSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup C	100 percentage of participants

Secondary

Percentage of Participants With >= 4-Fold Rise in rSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3

Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by rSBA assay. Fold-rise was calculated as ratio of post-vaccination titer (i.e., 30 days post-vaccination at the age of 12 to 13 months) to pre-dose titer before vaccination at the age of 3 months.

Time frame: Before vaccination at the age of 3 months, 30 days post-vaccination at the age of 12 to 13 months (i.e., at the age of 13 to 14 months)

Arm	Measure	Group	Value (NUMBER)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With >= 4-Fold Rise in rSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup A	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With >= 4-Fold Rise in rSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup C	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With >= 4-Fold Rise in rSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup Y	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With >= 4-Fold Rise in rSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup W	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With >= 4-Fold Rise in rSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup W	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With >= 4-Fold Rise in rSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup A	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With >= 4-Fold Rise in rSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup Y	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With >= 4-Fold Rise in rSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup C	100 percentage of participants

Secondary

Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1

Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Infancy was defined as up to 4 months of age. Percentage of participants with hSBA antibody titers distribution \<1:4, \>=1:4, \>=1:8, \>=1:16; \>=1:32; \>=1:64, \>=1:128, \>=1:256; \>=1:512; \>=1:1024 for meningococcal serogroups A, C, Y, and W were reported in this outcome measure.

Time frame: 30 days post-vaccination at the age of 3 months (i.e., at the age of 4 months)

Population: Analysis was performed on PPAS1. Here, 'number analyzed' = participants with available data for each specified category and '0' in the number analyzed field denotes that no participant had available data for the specified titer category.

Arm	Measure	Group	Value (NUMBER)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:64	7.8 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:1024	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:64	66.2 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:8	73.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:512	1.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:128	54.5 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:64	2.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:256	1.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:256	32.5 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:128	1.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:512	20.8 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:4	87.5 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:1024	6.5 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:32	5.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: <1:4	18.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:256	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:128	4.2 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:4	81.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:512	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:64	7.0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:8	66.2 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:512	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:32	21.1 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:16	40.8 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:16	51.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:1024	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: <1:4	12.5 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: <1:4	6.5 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:256	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:16	21.1 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:4	93.5 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:32	21.9 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:8	35.5 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:8	87.0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:1024	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:4	56.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:16	85.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:128	1.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: <1:4	43.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:32	81.8 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:1024	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: <1:4	14.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:4	85.9 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:8	66.2 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:16	42.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:32	19.7 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:64	9.9 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:128	2.8 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:256	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:512	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:1024	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: <1:4	9.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:4	90.9 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:8	88.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:16	80.5 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:32	71.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:64	66.2 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:128	49.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:256	28.6 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:512	13.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:1024	5.2 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: <1:4	30.9 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:4	69.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:8	54.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:16	25.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:32	11.8 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:64	4.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:128	1.5 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:256	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:512	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:1024	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: <1:4	53.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:4	46.6 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:8	27.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:16	13.7 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:32	4.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:64	1.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:128	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:256	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:512	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:64	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:16	6.0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:32	16.7 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: <1:4	94.8 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:8	7.1 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: <1:4	21.2 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:4	5.2 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:4	21.4 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:128	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:8	2.6 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: <1:4	78.6 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:16	34.8 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:16	1.3 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:16	2.7 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:8	2.7 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:128	3.0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:32	1.4 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:4	11.0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:4	78.8 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:64	1.4 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: <1:4	89.0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:32	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:128	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:128	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:64	9.1 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:64	1.2 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:8	51.5 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:32	3.6 percentage of participants

Secondary

Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3

Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Percentage of participants with hSBA antibody titers distribution \<1:4, \>=1:4, \>=1:8, \>=1:16; \>=1:32; \>=1:64, \>=1:128, \>=1:256; \>=1:512; \>=1:1024; \>=1:2048; \>=1:4096; \>=1:8192; \>=1:16384; \>=1:32768; \>=1:65536 for meningococcal serogroups A, C, Y, and W were reported in this outcome measure.

Time frame: 30 days post-vaccination at the age of 12 to 13 months (i.e., at the age of 13 to 14 months)

Population: Analysis was performed on PPAS3. Here, 'number analyzed' = participants with available data for each specified category and '0' in the number analyzed field denotes that no participant had available data for the specified titer category.

Arm	Measure	Group	Value (NUMBER)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:16384	0.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:8	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:16	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:32	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:64	99.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:128	97.5 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:256	94.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:512	83.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:1024	68.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:2048	39.0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:4096	25.2 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:8192	10.1 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:16384	6.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:32768	0.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: <1:4	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:4	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:8	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:16	99.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:32	98.2 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:64	97.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:128	95.2 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:256	90.5 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:512	78.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:1024	64.9 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:2048	35.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:4096	22.0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:8192	8.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:32768	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: <1:4	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:4	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:8	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:16	99.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:32	98.8 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:64	94.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:128	89.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:256	77.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:512	65.2 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:1024	39.1 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:2048	11.2 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:4096	5.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:8192	1.9 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:16384	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:32768	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: <1:4	0.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:4	99.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:8	99.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:16	98.8 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:32	98.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:64	98.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:128	93.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:256	84.9 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:512	70.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:1024	45.9 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:2048	15.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:4096	9.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:8192	2.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:16384	1.2 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:32768	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: <1:4	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:4	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:32768	1.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:512	61.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:128	93.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:4	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:4	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:8192	3.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:8	99.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:8192	1.9 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:4096	14.5 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:16	98.7 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:8	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:2048	13.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:32	94.2 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:512	73.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:16384	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:64	87.2 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:16384	1.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:16	99.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:128	75.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:64	98.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:256	85.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:256	58.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:32	98.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:32768	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:512	35.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:8192	5.5 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:64	98.2 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:1024	17.9 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:64	95.6 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:16384	0.6 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:2048	1.9 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:32	98.8 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:128	89.9 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:1024	58.2 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:4096	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:512	64.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: <1:4	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:8192	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:256	81.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:32768	0.6 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:16384	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:16	99.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:4096	4.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:32768	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:256	86.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:4	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: <1:4	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: <1:4	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:1024	32.7 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:4	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:2048	25.5 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:1024	43.8 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:8	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:2048	9.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:8	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:16	99.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: <1:4	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:128	92.7 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:32	99.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:4096	5.7 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:8	78.8 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:16	69.4 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:8	2.3 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:65536	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:32	56.5 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:64	30.6 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:128	22.4 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:16	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:256	7.1 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:512	4.7 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:1024	2.4 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:32	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:2048	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:8192	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:4096	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:8192	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:16384	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:64	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:32768	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:65536	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: <1:4	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: <1:4	46.3 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:4	53.7 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:128	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:8	35.4 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:16	23.2 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:32	6.1 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:256	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:64	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:16384	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:128	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:256	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:512	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:512	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:1024	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:2048	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:1024	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:4096	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:4	100 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:8	100 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:8192	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:16	100 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:32	97.5 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:64	93.8 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:16384	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:128	90.0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:2048	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:256	83.8 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:512	76.3 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:32768	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:1024	52.5 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:65536	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:2048	26.3 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:32768	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:65536	1.3 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:4096	15.0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:8192	5.0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: <1:4	96.5 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:16384	2.5 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:32768	1.3 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: <1:4	10.6 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:4	3.5 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:4	89.4 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:4096	0 percentage of participants

Secondary

Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1

Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Percentage of participants with hSBA antibody titers distribution \<1:4, \>=1:4, \>=1:8, \>=1:16; \>=1:32; \>=1:64, \>=1:128, \>=1:256; \>=1:512; \>=1:1024 for meningococcal serogroups A, C, Y, and W were reported in this outcome measure.

Time frame: Before vaccination at the age of 3 months

Arm	Measure	Group	Value (NUMBER)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:32	4.2 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:256	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:32	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:32	22.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:128	3.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:64	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:256	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:64	3.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:128	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:16	4.2 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:32	3.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:256	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:64	4.5 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:512	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:4	81.8 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:1024	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:8	8.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: <1:4	70.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:128	4.5 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:16	7.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:4	29.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:1024	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:8	22.2 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:4	16.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:256	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:128	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:512	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:8	59.1 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:1024	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: <1:4	18.2 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: <1:4	44.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:64	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: <1:4	83.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:4	55.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:16	36.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:1024	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:8	25.9 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:512	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:512	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:16	7.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:1024	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: <1:4	25.9 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:4	74.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:8	48.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:16	33.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:32	11.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:64	7.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:128	7.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:256	3.7 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:512	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:1024	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: <1:4	61.8 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:4	38.2 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:8	20.6 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:16	11.8 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:32	5.9 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:64	5.9 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:128	5.9 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:256	2.9 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:512	2.9 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:1024	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: <1:4	73.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:4	26.7 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:8	10.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:16	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:32	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:64	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:128	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:256	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:512	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:1024	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: <1:4	89.7 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:8	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:16	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:32	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:64	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:128	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:256	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:512	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:4	10.3 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:8	14.3 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:8	48.3 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:4	37.1 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: <1:4	24.1 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: <1:4	62.9 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:64	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: <1:4	87.5 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:128	3.4 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:64	10.3 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:4	75.9 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:8	3.1 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:4	15.2 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:32	20.7 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:8	12.1 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: <1:4	84.8 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:4	12.5 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:16	3.0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:128	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:16	3.1 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:32	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:64	2.9 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:16	27.6 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:64	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:32	2.9 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:128	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:128	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:16	11.4 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:32	3.1 percentage of participants

Secondary

Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3

Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Infancy was defined as up to 4 months of age. Percentage of participants with hSBA antibody titers distribution \<1:4, \>=1:4, \>=1:8, \>=1:16; \>=1:32; \>=1:64, \>=1:128, \>=1:256; \>=1:512; \>=1:1024; \>=1:2048; \>=1:4096; \>=1:8192; \>=1:16384; \>=1:32768; \>=1:65536 for meningococcal serogroups A, C, Y, and W were reported in this outcome measure.

Time frame: Before vaccination at the age of 12 to 13 months

Population: Analysis was performed on PPAS3. Here, 'overall number of participants analyzed' = participants with available data for this outcome measure and 'number analyzed' = participants with available data for each specified category. Here, '0' in the number analyzed field denotes that no participant had available data for the specified titer category.

Arm	Measure	Group	Value (NUMBER)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:256	6.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:4	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:512	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:8192	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:1024	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:2048	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:4096	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:8192	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:16384	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:16384	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:1024	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:32768	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:32768	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: <1:4	2.9 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:8	93.5 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:4	97.1 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:8	88.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: <1:4	5.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:16	77.1 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:32	60.0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:16	90.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:64	45.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:4	94.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:128	28.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:256	8.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:512	5.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:8	85.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:4096	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:8192	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:16	71.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:16384	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:32768	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:32	64.5 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:32	65.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:64	48.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:64	48.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:128	20.0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:256	5.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:128	29.0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:512	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:2048	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:1024	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:256	22.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:2048	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:4096	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:8192	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:512	3.2 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:16384	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:32768	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: <1:4	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:1024	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: <1:4	3.1 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:4	96.9 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:8	93.8 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:2048	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:16	78.1 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:32	50.0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:64	28.1 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:4096	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:128	12.5 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:4096	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:32768	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:16	42.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:512	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:16384	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:512	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:1024	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:8192	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:32	34.6 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:2048	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:4	96.2 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:16	34.6 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:4096	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:32768	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:8192	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:64	3.8 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:64	23.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:16384	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:2048	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:128	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:32768	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:128	15.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:32768	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:256	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: <1:4	15.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:256	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:32	19.2 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:4	84.6 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:8	76.9 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: <1:4	11.5 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:8	69.2 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:512	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:1024	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:16	46.2 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: <1:4	26.9 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:32	61.5 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:32	23.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:1024	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:4	88.5 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:64	11.5 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: <1:4	3.8 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:2048	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:128	3.8 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:4	73.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:256	3.8 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:256	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:16	73.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:128	3.8 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:512	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:4096	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:2048	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:8	53.8 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:16384	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:4096	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:1024	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:8	73.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:8192	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:8192	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:64	11.5 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:16384	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:65536	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:32	41.2 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:4096	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:1024	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:16384	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: <1:4	11.8 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:4	88.2 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:16	55.9 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:64	29.4 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:128	23.5 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:256	5.9 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:512	2.9 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:1024	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:2048	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:4096	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:8192	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:16384	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:32768	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:65536	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: <1:4	94.3 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:4	5.7 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:8	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:16	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:32	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:64	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:128	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:256	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:512	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:1024	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:2048	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:4096	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:8192	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:16384	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:32768	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:65536	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: <1:4	94.3 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:4	5.7 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:8	5.7 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:16	2.9 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:32	2.9 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:64	2.9 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:128	2.9 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:256	2.9 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:512	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:1024	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:2048	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:8192	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:16384	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:32768	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:65536	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: <1:4	100 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:4	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:8	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:16	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:32	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:64	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:128	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:256	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:512	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:2048	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:4096	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:8192	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:32768	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:8	73.5 percentage of participants

Secondary

Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1

Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by rSBA assay. Infancy was defined as up to 4 months of age. Percentage of participants with rSBA antibody titers distribution \<1:4, \>=1:4, \>=1:8, \>=1:16; \>=1:32; \>=1:64, \>=1:128, \>=1:256; \>=1:512; \>=1:1024; \>=1:2048; \>=1:4096; \>=1:8192 for meningococcal serogroups A, C, Y, and W were reported in this outcome measure.

Time frame: 30 days post-vaccination at the age of 3 months (i.e., at the age of 4 months)

Population: Analysis was performed on PPAS1. Here, 'overall number of participants analyzed' = participants with available data for this outcome measure and 'number analyzed' = participants with available data for each specified category. Here, '0' in the number analyzed field denotes that no participant had available data for the specified titer category.

Arm	Measure	Group	Value (NUMBER)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:32	89.5 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:128	75.0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:1024	5.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:64	81.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:64	36.1 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:512	36.1 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:128	78.9 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:2048	5.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:256	63.9 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:256	71.1 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:64	75.0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:128	80.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:512	55.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:128	19.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:64	80.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:1024	23.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:4	61.1 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:32	83.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:2048	5.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:32	75.0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:16	88.9 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:4096	2.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:256	8.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:8192	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:8192	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: <1:4	8.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:16	77.8 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:8	91.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:4	91.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:512	5.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:1024	11.1 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:8	77.8 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:1024	5.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:8	52.8 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:4	77.8 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:2048	2.8 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:4096	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: <1:4	22.2 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:4096	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:512	19.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:8192	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:16	44.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: <1:4	2.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: <1:4	38.9 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:256	50.0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:8192	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:8	97.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:32	41.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:4096	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:16	94.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:4	97.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:2048	2.8 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:8192	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:4	92.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: <1:4	21.9 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:4	78.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:8	65.6 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:16	53.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:32	43.8 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:64	31.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:128	28.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:256	21.9 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:512	9.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:1024	3.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:2048	3.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:4096	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:8192	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: <1:4	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:4	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:8	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:16	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:32	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:64	96.9 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:128	96.9 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:256	65.6 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:512	40.6 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:1024	28.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:2048	9.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:4096	3.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:8192	3.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: <1:4	8.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:8	92.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:16	88.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:32	80.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:64	72.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:128	68.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:256	48.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:512	36.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:1024	12.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:2048	4.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:4096	4.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:8192	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: <1:4	33.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:4	66.7 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:8	63.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:16	63.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:32	63.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:64	63.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:128	53.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:256	50.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:512	26.7 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:1024	13.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:2048	3.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:4096	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:1024	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:1024	3.2 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:16	5.4 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:128	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:2048	3.2 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:8	8.1 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:16	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:4	13.5 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: <1:4	97.2 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:2048	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:256	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: <1:4	100 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:1024	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:8	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:4	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:512	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:2048	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:8	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:256	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:512	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:16	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:4	9.7 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: <1:4	90.3 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:128	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:8	9.7 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:2048	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:4	2.8 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:16	9.7 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:1024	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:32	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:32	6.5 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:512	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:64	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:64	3.2 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:256	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: <1:4	86.5 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:128	3.2 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:128	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup W: >=1:64	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:256	3.2 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:64	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup A: >=1:32	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup Y: >=1:512	3.2 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1	Serogroup C: >=1:32	5.4 percentage of participants

Secondary

Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3

Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by rSBA assay. Percentage of participants with rSBA antibody titers distribution \<1:4, \>=1:4, \>=1:8, \>=1:16; \>=1:32; \>=1:64, \>=1:128, \>=1:256; \>=1:512; \>=1:1024; \>=1:2048; \>=1:4096; \>=1:8192; \>=1:16384; \>=1:32768 for meningococcal serogroups A, C, Y, and W were reported in this outcome measure.

Time frame: 30 days post-vaccination at the age of 12 to 13 months (i.e., at the age of 13 to 14 months)

Population: Analysis was performed on PPAS3. Here, 'overall number of participants analyzed' = participants with available data for this outcome measure and 'number analyzed' = participants with available data for each specified category. Here, '0' in the number analyzed field denotes that no participant had available data for the specified titer category.

Arm	Measure	Group	Value (NUMBER)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:64	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:512	97.8 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:8192	17.8 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:128	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:128	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:4096	44.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:256	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:4	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:2048	77.8 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:512	89.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:256	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:1024	93.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:256	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:512	97.8 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:2048	51.1 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:256	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:4096	21.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:128	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:128	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:8192	8.5 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:512	97.9 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:16384	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:8192	28.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:32768	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:64	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: <1:4	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:1024	87.2 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:64	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:4	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:8	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:32	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:8	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:32	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:16	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:2048	53.2 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:32768	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:16	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:4096	29.8 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:4096	39.1 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:8	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:8192	6.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:16	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:16384	2.1 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: <1:4	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:32768	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:2048	73.9 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: <1:4	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:32	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:4	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:4	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:1024	74.5 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: <1:4	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:8	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:1024	87.0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:16	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:64	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:32768	2.2 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:32	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:16384	2.2 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:16384	2.2 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:32768	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: <1:4	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:4	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:8	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:16	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:32	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:64	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:128	97.7 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:256	97.7 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:512	88.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:1024	79.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:2048	51.2 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:4096	32.6 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:8192	9.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:16384	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:32768	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: <1:4	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:4	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:8	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:16	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:32	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:64	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:128	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:256	95.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:512	88.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:1024	72.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:2048	53.5 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:4096	34.9 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:8192	9.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:16384	4.7 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:32768	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: <1:4	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:4	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:8	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:16	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:32	97.7 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:64	97.7 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:128	97.7 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:256	95.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:512	95.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:1024	79.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:2048	53.5 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:4096	20.9 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:8192	9.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:16384	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:32768	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: <1:4	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:4	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:8	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:16	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:32	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:64	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:128	97.7 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:256	97.7 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:512	95.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:1024	86.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:2048	74.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:4096	46.5 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:8192	25.6 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:16384	9.3 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:4096	11.6 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:64	11.4 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:64	85.4 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:32	11.4 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:4	85.4 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:16	11.4 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:512	2.4 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:4	11.4 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:32	85.4 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: <1:4	81.0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: <1:4	88.6 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:1024	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:4	19.0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:4096	17.1 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:16	85.4 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:8	16.7 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:2048	36.6 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: <1:4	14.6 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:16	16.7 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:1024	51.2 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:2048	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:32	16.7 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:8	93.0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:512	68.3 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:16	93.0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:4	93.0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:8	85.4 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:32	93.0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: <1:4	7.0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:64	16.7 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:64	93.0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:4096	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:256	75.6 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:128	93.0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:2048	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:8	11.4 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:256	90.7 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:1024	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:128	11.9 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:512	79.1 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:512	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup A: >=1:128	85.4 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:1024	67.4 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:256	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:4096	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup Y: >=1:2048	46.5 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup C: >=1:128	9.1 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3	Serogroup W: >=1:256	4.8 percentage of participants

Secondary

Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1

Time frame: Before vaccination at the age of 3 months

Population: Analysis was performed on PPAS1. Here, 'overall number of participants analyzed' = participants with available data for this outcome measure and 'number analyzed' = participants with available data for each specified category. Here, '0' in the number analyzed field denotes that no participant had available data for the specified titer category.

Arm	Measure	Group	Value (NUMBER)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:2048	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:64	5.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:256	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:1024	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:128	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:128	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:512	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:256	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:4096	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:256	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:512	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:128	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:128	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:1024	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:256	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:64	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:2048	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:8	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:32	10.5 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:4096	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:32	11.8 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:8192	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:512	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: <1:4	89.5 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:64	5.9 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:16	10.5 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:4	10.5 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:16	11.8 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:8	10.5 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:1024	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:2048	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:2048	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:16	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:8	11.8 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:4096	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:8192	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:8192	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:1024	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: <1:4	84.2 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:32	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:4	11.8 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:4	15.8 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:4	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: <1:4	88.2 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:8	15.8 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:512	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:8192	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:16	10.5 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:64	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:4096	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:32	5.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: <1:4	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:8192	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: <1:4	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:4	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:8	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:16	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:32	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:64	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:128	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:256	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:512	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:1024	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:2048	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:4096	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:8192	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: <1:4	82.6 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:4	17.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:8	17.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:16	17.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:32	17.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:64	13.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:128	4.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:256	4.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:512	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:1024	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:2048	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:4096	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:8192	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: <1:4	87.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:4	13.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:8	13.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:16	8.7 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:32	4.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:64	4.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:128	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:256	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:512	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:1024	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:2048	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:4096	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:8192	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: <1:4	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:4	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:8	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:16	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:32	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:64	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:128	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:256	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:512	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:1024	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:2048	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:4096	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:1024	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:32	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:2048	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:2048	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:16	7.7 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:256	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:8	11.5 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:32	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:4	15.4 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:4	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: <1:4	96.2 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: <1:4	84.6 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:512	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:4	3.8 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:2048	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:16	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:8	3.8 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:512	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:1024	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:16	3.8 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:256	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:4	15.4 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:1024	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:8	15.4 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: <1:4	84.6 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:32	3.8 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:16	7.7 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:2048	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:8	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:32	3.8 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:1024	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:64	3.8 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:64	3.8 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:512	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:128	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:128	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:256	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: <1:4	100 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:256	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:128	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup W: >=1:128	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup Y: >=1:512	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup C: >=1:64	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1	Serogroup A: >=1:64	0 percentage of participants

Secondary

Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3

Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by rSBA assay. Infancy was defined as up to 4 months of age. Percentage of participants with rSBA antibody titers distribution \<1:4, \>=1:4, \>=1:8, \>=1:16; \>=1:32; \>=1:64, \>=1:128, \>=1:256; \>=1:512; \>=1:1024; \>=1:2048; \>=1:4096; \>=1:8192; \>=1:16384; \>=1:32768 for meningococcal serogroups A, C, Y, and W were reported in this outcome measure.

Time frame: Before vaccination at the age of 12 to 13 months

Population: Analysis was performed on PPAS3. Here, 'overall number of participants analyzed' = participants with available data for this outcome measure and 'number analyzed' = participants with available data for each specified category. Here, '0' in the number analyzed field denotes that no participant had available data for the specified titer category.

Arm	Measure	Group	Value (NUMBER)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:64	71.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:512	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:16384	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:128	42.9 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:8192	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:256	14.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:256	33.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:4096	14.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:512	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:8	50.0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:2048	14.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:1024	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:256	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:1024	14.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:2048	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:512	33.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:512	14.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:4096	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:128	50.0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:256	14.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:8192	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:128	20.0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:16384	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:1024	33.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:32768	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:8192	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: <1:4	14.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:2048	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:128	28.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:4	85.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:16	50.0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:64	57.1 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:8	85.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:64	20.0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:32	71.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:16	85.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:4096	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:32768	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:32	20.0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:8192	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:4096	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:16384	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:32	50.0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:32768	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:4	50.0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: <1:4	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:2048	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:16	40.0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:4	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:64	50.0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:8	40.0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:8	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: <1:4	50.0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:4	60.0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:16	85.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:1024	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: <1:4	40.0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:32	71.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:16384	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:32768	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:32768	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:128	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:4096	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:8	60.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: <1:4	20.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:4	80.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:8	80.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:16	80.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:32	80.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:64	80.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:128	80.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:256	60.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:512	40.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:1024	40.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:2048	20.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:4096	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:8192	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:16384	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:32768	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: <1:4	80.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:4	20.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:8	20.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:16	20.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:32	20.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:64	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:256	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:512	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:1024	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:2048	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:4096	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:8192	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:16384	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:32768	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: <1:4	40.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:4	60.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:8	40.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:16	40.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:32	20.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:64	20.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:128	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:256	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:512	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:1024	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:2048	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:8192	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:16384	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:32768	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: <1:4	40.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:4	60.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:16	40.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:32	20.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:64	20.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:128	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:256	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:512	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:1024	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:2048	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:4096	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:8192	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:16384	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:4096	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:128	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:512	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:64	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:64	50.0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:32	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: <1:4	50.0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:16	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:1024	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: <1:4	100 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:8	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:32	50.0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:4	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:4	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:8	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: <1:4	100 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:4	50.0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:16	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:4096	16.7 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:2048	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:32	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:2048	16.7 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:16	50.0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:64	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:512	33.3 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:16	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:8	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:1024	16.7 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:32	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:4	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:128	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:64	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: <1:4	100 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:256	33.3 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:128	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:4096	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:4096	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:256	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:2048	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup W: >=1:256	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:512	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:1024	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:128	33.3 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:1024	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:512	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup A: >=1:8	50.0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup Y: >=1:2048	0 percentage of participants
Group 3: Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3	Serogroup C: >=1:256	0 percentage of participants

Secondary

Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1

Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Infancy was defined as up to 4 months of age. Percentage of participants with antibody titers \>=1.4 and \>=1:8 for meningococcal serogroups A, C, Y, and W were reported in this outcome measure.

Time frame: 30 days post-vaccination at the age of 3 months (i.e., at the age of 4 months)

Arm	Measure	Group	Value (NUMBER)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup A: >= 1:4	87.5 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup A: >= 1:8	73.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup C: >= 1:4	93.5 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup C: >= 1:8	87.0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup Y: >= 1:4	81.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup Y: >= 1:8	66.2 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup W: >= 1:4	56.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup W: >= 1:8	35.5 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup W: >= 1:8	27.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup A: >= 1:4	85.9 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup Y: >= 1:4	69.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup A: >= 1:8	66.2 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup W: >= 1:4	46.6 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup C: >= 1:4	90.9 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup Y: >= 1:8	54.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup C: >= 1:8	88.3 percentage of participants

Secondary

Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3

Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Percentage of participants with antibody titers \>=1.4 and \>=1:8 for meningococcal serogroups A, C, Y, and W were reported in this outcome measure.

Time frame: 30 days post-vaccination at the age of 12 to 13 months (i.e., at the age of 13 to 14 months)

Arm	Measure	Group	Value (NUMBER)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup A: >= 1:4	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup A: >= 1:8	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup C: >= 1:4	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup C: >= 1:8	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup Y: >= 1:4	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup Y: >= 1:8	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup W: >= 1:4	99.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup W: >= 1:8	99.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup W: >= 1:8	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup A: >= 1:4	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup Y: >= 1:4	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup A: >= 1:8	99.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup W: >= 1:4	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup C: >= 1:4	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup Y: >= 1:8	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup C: >= 1:8	100 percentage of participants

Secondary

Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1

Time frame: Before vaccination at the age of 3 months

Arm	Measure	Group	Value (NUMBER)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup A: >= 1:4	81.8 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup A: >= 1:8	59.1 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup C: >= 1:4	55.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup C: >= 1:8	25.9 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup Y: >= 1:4	29.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup Y: >= 1:8	22.2 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup W: >= 1:4	16.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup W: >= 1:8	8.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup W: >= 1:8	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup A: >= 1:4	74.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup Y: >= 1:4	26.7 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup A: >= 1:8	48.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup W: >= 1:4	10.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup C: >= 1:4	38.2 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup Y: >= 1:8	10.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup C: >= 1:8	20.6 percentage of participants

Secondary

Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3

Time frame: Before vaccination at the age of 12 to 13 months

Arm	Measure	Group	Value (NUMBER)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup W: >= 1:4	97.1 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup C: >= 1:4	94.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup A: >= 1:4	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup C: >= 1:8	85.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup W: >= 1:8	88.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup Y: >= 1:4	96.9 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup A: >= 1:8	93.5 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup Y: >= 1:8	93.8 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup A: >= 1:8	76.9 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup W: >= 1:4	84.6 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup W: >= 1:8	69.2 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup A: >= 1:4	96.2 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup Y: >= 1:8	73.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup C: >= 1:4	73.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup C: >= 1:8	53.8 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup Y: >= 1:4	88.5 percentage of participants

Secondary

Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W - PPAS2

Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Percentage of participants with hSBA antibody titers \>=1.4 and \>=1:8 for meningococcal serogroups A, C, Y, and W were reported in this outcome measure.

Time frame: 30 days post-vaccination at the age of 3 months (i.e., at the age of 4 months) and before vaccination at the age of 12-13 months

Population: Analysis was performed on PPAS2. Here, 'number analyzed' = participants with available data for each specified category. Data for this outcome measure was not planned to be collected and analyzed for Group 3.

Arm	Measure	Group	Value (NUMBER)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup Y: 30 days after 3-month vaccination: >= 1:4	75.9 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup C: 30 days after 3-month vaccination: >= 1:4	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup Y: 30 days after 3-month vaccination: >= 1:8	65.5 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup A: Before 12-13 months vaccination: >= 1:8	91.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup Y: Before 12-13 months vaccination: >= 1:4	94.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup C: 30 days after 3-month vaccination: >= 1:8	92.9 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup Y: Before 12-13 months vaccination: >= 1:8	89.5 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup A: 30 days after 3-month vaccination: >= 1:8	81.5 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup W: 30 days after 3-month vaccination: >= 1:4	51.9 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup C: Before 12-13 months vaccination: >= 1:4	87.8 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup W: 30 days after 3-month vaccination: >= 1:8	37.0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup A: 30 days after 3-month vaccination: >= 1:4	88.9 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup W: Before 12-13 months vaccination: >= 1:4	92.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup C: Before 12-13 months vaccination: >= 1:8	80.5 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup W: Before 12-13 months vaccination: >= 1:8	85.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup A: Before 12-13 months vaccination: >= 1:4	97.2 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup W: Before 12-13 months vaccination: >= 1:8	68.6 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup A: Before 12-13 months vaccination: >= 1:8	83.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup A: 30 days after 3-month vaccination: >= 1:4	89.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup A: 30 days after 3-month vaccination: >= 1:8	64.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup C: 30 days after 3-month vaccination: >= 1:4	96.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup C: 30 days after 3-month vaccination: >= 1:8	92.9 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup C: Before 12-13 months vaccination: >= 1:4	80.6 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup C: Before 12-13 months vaccination: >= 1:8	69.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup Y: 30 days after 3-month vaccination: >= 1:4	57.7 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup Y: 30 days after 3-month vaccination: >= 1:8	46.2 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup Y: Before 12-13 months vaccination: >= 1:4	90.9 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup Y: Before 12-13 months vaccination: >= 1:8	78.8 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup W: 30 days after 3-month vaccination: >= 1:4	39.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup W: 30 days after 3-month vaccination: >= 1:8	28.6 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup W: Before 12-13 months vaccination: >= 1:4	88.6 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup A: Before 12-13 months vaccination: >= 1:4	97.2 percentage of participants

Secondary

Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1

Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by rSBA assay. Infancy was defined as up to 4 months of age. Percentage of participants with antibody titers \>=1.8 and \>=1:128 for meningococcal serogroups A, C, Y, and W were reported in this outcome measure.

Time frame: 30 days post-vaccination at the age of 3 months (i.e., at the age of 4 months)

Arm	Measure	Group	Value (NUMBER)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup A: >= 1:8	52.8 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup A: >= 1:128	19.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup C: >= 1:8	97.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup C: >= 1:128	78.9 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup Y: >= 1:8	91.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup Y: >= 1:128	80.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup W: >= 1:8	77.8 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup W: >= 1:128	75.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup W: >= 1:128	53.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup A: >= 1:8	65.6 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup Y: >= 1:8	92.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup A: >= 1:128	28.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup W: >= 1:8	63.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup C: >= 1:8	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup Y: >= 1:128	68.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup C: >= 1:128	96.9 percentage of participants

Secondary

Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3

Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by rSBA assay. Percentage of participants with antibody titers \>=1.8 and \>=1:128 for meningococcal serogroups A, C, Y, and W were reported in this outcome measure.

Time frame: 30 days post-vaccination at the age of 12 to 13 months (i.e., at the age of 13 to 14 months)

Arm	Measure	Group	Value (NUMBER)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup C: >= 1:128	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup A: >= 1:128	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup Y: >= 1:8	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup A: >= 1:8	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup Y: >= 1:128	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup C: >= 1:8	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup W: >= 1:128	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup W: >= 1:8	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup W: >= 1:128	97.7 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup A: >= 1:8	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup A: >= 1:128	97.7 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup C: >= 1:8	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup C: >= 1:128	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup Y: >= 1:8	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup W: >= 1:8	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup Y: >= 1:128	97.7 percentage of participants

Secondary

Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1

Time frame: Before vaccination at the age of 3 months

Arm	Measure	Group	Value (NUMBER)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup Y: >= 1:8	10.5 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup C: >= 1:8	15.8 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup Y: >= 1:128	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup A: >= 1:8	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup W: >= 1:8	11.8 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup C: >= 1:128	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup W: >= 1:128	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup A: >= 1:128	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup W: >= 1:128	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup A: >= 1:8	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup C: >= 1:8	17.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup C: >= 1:128	4.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup Y: >= 1:8	13.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup Y: >= 1:128	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup W: >= 1:8	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1	Serogroup A: >= 1:128	0 percentage of participants

Secondary

Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3

Time frame: Before vaccination at the age of 12 to 13 months

Arm	Measure	Group	Value (NUMBER)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup A: >= 1:8	50.0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup A: >= 1:128	50.0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup C: >= 1:8	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup C: >= 1:128	42.9 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup Y: >= 1:8	85.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup Y: >= 1:128	28.6 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup W: >= 1:8	40.0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup W: >= 1:128	20.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup W: >= 1:128	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup A: >= 1:8	80.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup Y: >= 1:8	40.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup A: >= 1:128	80.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup W: >= 1:8	60.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup C: >= 1:8	20.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup Y: >= 1:128	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3	Serogroup C: >= 1:128	0 percentage of participants

Secondary

Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W - PPAS2

Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by rSBA assay. Percentage of participants with rSBA antibody titers \>=1:8 and \>=1:128 for meningococcal serogroups A, C, Y, and W were reported in this outcome measure.

Time frame: 30 days post-vaccination at the age of 3 months (i.e., at the age of 4 months) and before vaccination at the age of 12-13 months

Arm	Measure	Group	Value (NUMBER)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup A: 30 days after 3-month vaccination: >= 1:8	66.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup Y: 30 days after 3-month vaccination: >= 1:8	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup C: 30 days after 3-month vaccination: >= 1:8	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup Y: 30 days after 3-month vaccination: >= 1:128	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup A: Before 12-13 months vaccination: >= 1:8	42.9 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup Y: Before 12-13 months vaccination: >= 1:8	87.5 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup C: 30 days after 3-month vaccination: >= 1:128	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup Y: Before 12-13 months vaccination: >= 1:128	37.5 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup A: 30 days after 3-month vaccination: >= 1:128	66.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup W: 30 days after 3-month vaccination: >= 1:8	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup C: Before 12-13 months vaccination: >= 1:8	87.5 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup W: 30 days after 3-month vaccination: >= 1:128	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup A: Before 12-13 months vaccination: >= 1:128	42.9 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup W: Before 12-13 months vaccination: >= 1:8	50.0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup C: Before 12-13 months vaccination: >= 1:128	37.5 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup W: Before 12-13 months vaccination: >= 1:128	33.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup C: Before 12-13 months vaccination: >= 1:128	11.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup A: 30 days after 3-month vaccination: >= 1:8	66.7 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup A: 30 days after 3-month vaccination: >= 1:128	16.7 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup A: Before 12-13 months vaccination: >= 1:8	55.6 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup A: Before 12-13 months vaccination: >= 1:128	44.4 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup C: 30 days after 3-month vaccination: >= 1:8	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup C: 30 days after 3-month vaccination: >= 1:128	83.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup C: Before 12-13 months vaccination: >= 1:8	55.6 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup W: Before 12-13 months vaccination: >= 1:128	0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup Y: 30 days after 3-month vaccination: >= 1:8	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup Y: 30 days after 3-month vaccination: >= 1:128	50.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup Y: Before 12-13 months vaccination: >= 1:8	62.5 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup Y: Before 12-13 months vaccination: >= 1:128	25.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup W: 30 days after 3-month vaccination: >= 1:8	66.7 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup W: 30 days after 3-month vaccination: >= 1:128	66.7 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W - PPAS2	Serogroup W: Before 12-13 months vaccination: >= 1:8	33.3 percentage of participants

Secondary

Percentage of Participants With Vaccine Seroresponse Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1

The hSBA vaccine seroresponse against serogroups A, C, Y, and W was defined as post-vaccination hSBA titer \>=1:16 for participants with pre-vaccination hSBA titer \<1:8 or at least a 4-fold increase in hSBA titers from pre to post-vaccination for participants with pre-vaccination hSBA titers \>=1:8. Infancy was defined as up to 4 months of age.

Time frame: Before vaccination at the age of 3 months up to 30 days post-vaccination at the age of 3 months (i.e., at the age of 4 months)

Arm	Measure	Group	Value (NUMBER)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Vaccine Seroresponse Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup A	0 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Vaccine Seroresponse Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup C	66.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Vaccine Seroresponse Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup Y	33.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Vaccine Seroresponse Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup W	25.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Vaccine Seroresponse Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup W	11.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Vaccine Seroresponse Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup A	20.8 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Vaccine Seroresponse Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup Y	30.8 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Vaccine Seroresponse Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup C	79.4 percentage of participants

Secondary

Percentage of Participants With Vaccine Seroresponse Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3

Time frame: Before vaccination at the age of 3 months up to 30 days post-vaccination at the age of 12 to 13 months (i.e., at the age of 13 to 14 months)

Arm	Measure	Group	Value (NUMBER)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Vaccine Seroresponse Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup A	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Vaccine Seroresponse Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup C	92.9 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Vaccine Seroresponse Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup Y	96.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Vaccine Seroresponse Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup W	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Vaccine Seroresponse Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup W	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Vaccine Seroresponse Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup A	91.7 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Vaccine Seroresponse Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup Y	96.6 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Vaccine Seroresponse Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup C	93.8 percentage of participants

Secondary

Percentage of Participants With Vaccine Seroresponse Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3

Time frame: Before vaccination at the age of 12 to 13 months up to 30 days post-vaccination at the age of 12 to 13 months (i.e., at the age of 13 to 14 months)

Arm	Measure	Group	Value (NUMBER)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Vaccine Seroresponse Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup A	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Vaccine Seroresponse Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup Y	89.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Vaccine Seroresponse Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup C	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Vaccine Seroresponse Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup W	85.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Vaccine Seroresponse Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup W	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Vaccine Seroresponse Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup A	53.8 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Vaccine Seroresponse Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup C	96.2 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Vaccine Seroresponse Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup Y	96.0 percentage of participants

Secondary

Percentage of Participants With Vaccine Seroresponse Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1

The rSBA vaccine seroresponse against serogroups A, C, Y, and W was defined as post-vaccination rSBA titer \>=1:32 for participants with pre-vaccination rSBA titer \<1:8 or at least a 4-fold increase in hSBA titers from pre to post-vaccination for participants with pre-vaccination hSBA titers \>=1:8. Infancy was defined as up to 4 months of age.

Time frame: Before vaccination at the age of 3 months up to 30 days post-vaccination at the age of 3 months (i.e., at the age of 4 months)

Arm	Measure	Group	Value (NUMBER)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Vaccine Seroresponse Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup A	30.8 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Vaccine Seroresponse Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup C	86.7 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Vaccine Seroresponse Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup Y	71.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Vaccine Seroresponse Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup W	57.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Vaccine Seroresponse Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup W	53.3 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Vaccine Seroresponse Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup A	50.0 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Vaccine Seroresponse Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup Y	72.7 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Vaccine Seroresponse Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1	Serogroup C	87.5 percentage of participants

Secondary

Percentage of Participants With Vaccine Seroresponse Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3

Time frame: Before vaccination at the age of 12 to 13 months up to 30 days post-vaccination at the age of 12 to 13 months (i.e., at the age of 13 to 14 months)

Arm	Measure	Group	Value (NUMBER)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Vaccine Seroresponse Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup A	83.3 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Vaccine Seroresponse Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup C	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Vaccine Seroresponse Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup Y	71.4 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Vaccine Seroresponse Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup W	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Vaccine Seroresponse Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup W	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Vaccine Seroresponse Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup A	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Vaccine Seroresponse Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup Y	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Vaccine Seroresponse Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup C	100 percentage of participants

Secondary

Percentage of Participants With Vaccine Seroresponse Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3

Time frame: Before vaccination at the age of 3 months up to 30 days post-vaccination at the age of 12 to 13 months (i.e., at the age of 13 to 14 months)

Arm	Measure	Group	Value (NUMBER)
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Vaccine Seroresponse Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup A	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Vaccine Seroresponse Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup C	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Vaccine Seroresponse Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup Y	100 percentage of participants
Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)	Percentage of Participants With Vaccine Seroresponse Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup W	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Vaccine Seroresponse Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup W	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Vaccine Seroresponse Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup A	100 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Vaccine Seroresponse Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup Y	94.1 percentage of participants
Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)	Percentage of Participants With Vaccine Seroresponse Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3	Serogroup C	100 percentage of participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom

Conditions

Brief summary

Detailed description

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Recruitment details

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Percentage of Participants With Antibody Titers Greater Than or Equal to (>=) 1:8 Against Meningococcal Serogroups A, C, Y, and W Measured by hSBA After Vaccination: Groups 1 and 2 - PPAS3

Geometric Mean Titers (GMTs) of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3

Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1

Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3

Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1

Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3

Geometric Mean Titers of Antibodies Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2

Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1

Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3

Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1

Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3

Geometric Mean Titers of Antibodies Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W: Group 1 and 2 - PPAS2

Number of Participants With Solicited Injection Site Reactions After Any Vaccination

Number of Participants With Solicited Systemic Reactions After Any Vaccination

Percentage of Participants With >= 4-Fold Rise in hSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1

Percentage of Participants With >= 4-Fold Rise in hSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3

Percentage of Participants With >= 4-Fold Rise in hSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3

Percentage of Participants With >= 4-Fold Rise in rSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1

Percentage of Participants With >= 4-Fold Rise in rSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3

Percentage of Participants With >= 4-Fold Rise in rSBA Antibody Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3

Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1

Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3

Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1

Percentage of Participants With Distribution of hSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3

Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS1

Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W After Vaccination - PPAS3

Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS1

Percentage of Participants With Distribution of rSBA Titers Against Meningococcal Serogroups A, C, Y, and W Before Vaccination - PPAS3

Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1

Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3

Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1

Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3

Percentage of Participants With hSBA Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W - PPAS2

Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1

Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3

Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS1

Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W Before Vaccination: Group 1 and 2 - PPAS3

Percentage of Participants With rSBA Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W - PPAS2

Percentage of Participants With Vaccine Seroresponse Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1

Percentage of Participants With Vaccine Seroresponse Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3

Percentage of Participants With Vaccine Seroresponse Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3

Percentage of Participants With Vaccine Seroresponse Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS1

Percentage of Participants With Vaccine Seroresponse Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3

Percentage of Participants With Vaccine Seroresponse Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Vaccination: Group 1 and 2 - PPAS3